US FDA panel to mull JUPITER-based prevention indication for Crestor
27 October 2009
Sue Sutter
The US
FDA's endocrinologic and metabolic drugs advisory panel will meet on December 15th to consider
AstraZeneca's request to add a cardiovascular disease primary prevention claim for Crestor (rosuvastatin) based on data from the JUPITER trial.
The HMG-CoA reductase inhibitor is currently approved...
Please Login to read the full article.
27 October 2009
Sue Sutter
The HMG-CoA reductase inhibitor is currently approved...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US FDA considering striking statin use from labeling of Abbott's Trilipix
- FDA: Abbott's Trilipix may not lower heart, stroke risk; new trial ordered
- AIM-HIGH misses its mark, but hits Abbott and the "HDL hypothesis"
- FDA panel backs Merck's Vytorin in predialysis CKD, but rejects dialysis use
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
